EUVIMEDEUVIMED entdecken
Crossref

Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals

David González-de-Olano iD, Paula Navarro-Navarro iD, Javier I Muñoz-González iD, Laura Sánchez-Muñoz iD, Ana Henriques iD, Ana de-Andrés-Martín iD, Dolores Peralta-Arjonilla, Andrea Mayado iD, María Jara-Acevedo iD, Andrés C García-Montero iD, Alberto Orfao iD, Iván Álvarez-Twose iD

Allergy · 2024

DOI: 10.1111/all.15911 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2024. Verfasst von David González-de-Olano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain. Hauptthemen laut MEDLINE: Anaphylaxis, Mastocytosis, Mast Cell Activation Syndrome. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Fundación Española de Mastocitosis, Fundación para la investigación Biomédica del Hospital Ramón y Cajal IRYCIS, Fundación Sociedad Española de Alergología e Inmunología Clínica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A close association between hereditary alpha‐tryptasemia (HAT) and mast cell (MC) disorders has been previously reported. However, the relationship between HAT and the diagnostic subtypes and clinical features of MC disorders still remains to be established.

Objective

To determine the prevalence of HAT in healthy donors (HD) vs patients with different diagnostic subtypes of MC activation syndromes (MCAS) and mastocytosis, and its relationship with the clinical behavior of the disease.

Methods

A total of 959 subjects were studied including 346 healthy donors (HD), 464 mastocytosis, and 149 non‐clonal MCAS patients. Molecular studies to assess the TPSAB1 genotype were performed, and data on serum baseline tryptase (sBT) and basal MC‐mediator release episodes and triggers of anaphylaxis were collected.

Results

HAT was detected in 15/346 (4%) HD versus 43/149 (29%) non‐clonal MCAS and 84/464 (18%) mastocytosis cases. Among mastocytosis, HAT was more frequently found in patients with MC‐restricted KIT D816V (21% vs. 10% among multilineage KIT D816V patients; p = .008). Overall, median sBT was higher in cases presenting with HAT (28.9 vs. 24.5 ng/mL; p = .008), while no significant differences in sBT were observed among HAT + mastocytosis patients depending on the presence of 1 vs. ≥2 extra copies of the α‐tryptase gene (44.1 vs. 35.2 ng/mL, p > .05). In turn, anaphylaxis was more frequently observed in HAT + versus HAT − mastocytosis patients (76% vs. 65%; p = .018), while HAT + and HAT − patients who did not refer anaphylaxis as the presenting symptom ( n = 308) showed a similar prevalence of subsequent anaphylaxis (35% vs. 36%, respectively).

Conclusion

The frequency of HAT in MC disorders varies according to the diagnostic subtype of the disease. HAT does not imply a higher risk (and severity) of anaphylaxis in mastocytosis patients in whom anaphylaxis is not part of the presenting symptoms of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnaphylaxisMastocytosisMast Cell Activation SyndromeHumansMast CellsTryptasesGenotype

Stichwörter der Autor:innen

HATanaphylaxiscopy number mutationfrequencymastocytosis

Substanzen

TryptasesTPSAB1 protein, human

Autor:innen und Institutionen

  • Department of Allergy, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.
  • Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Salamanca, Spain.
  • Department of Medicine and Citometry Service (NUCLEUS), Cancer Research Center (IBMCC, USAL-CSIC), Universidad de Salamanca, Salamanca, Spain.
  • Sequencing Service (NUCLEUS), Universidad de Salamanca, Salamanca, Spain.
  • Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.
  • Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Virgen del Valle Hospital, Toledo, Spain.

ORCID-Profile: David González-de-Olano, Paula Navarro-Navarro, Javier I Muñoz-González, Laura Sánchez-Muñoz, Ana Henriques, Ana de-Andrés-Martín, Andrea Mayado, María Jara-Acevedo, Andrés C García-Montero, Alberto Orfao, Iván Álvarez-Twose

Förderung

  • Fundación Española de Mastocitosis
  • Fundación para la investigación Biomédica del Hospital Ramón y Cajal IRYCIS
  • Fundación Sociedad Española de Alergología e Inmunología Clínica
  • Instituto de Salud Carlos III (reference PI22/01657)

Zitieren

APA

González-de-Olano, D., Navarro-Navarro, P., Muñoz-González, J. I., Sánchez-Muñoz, L., Henriques, A., de-Andrés-Martín, A., Peralta-Arjonilla, D., Mayado, A., Jara-Acevedo, M., García-Montero, A. C., Orfao, A., & Álvarez-Twose, I. (2024). Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals. Allergy. https://doi.org/10.1111/all.15911

Vancouver

González-de-Olano D, Navarro-Navarro P, Muñoz-González JI, Sánchez-Muñoz L, Henriques A, de-Andrés-Martín A, et al. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals. Allergy. 2024. doi:10.1111/all.15911

BibTeX
@article{GonzlezdeOlano2024,
  author = {González-de-Olano, David and Navarro-Navarro, Paula and Muñoz-González, Javier I and Sánchez-Muñoz, Laura and Henriques, Ana and de-Andrés-Martín, Ana and Peralta-Arjonilla, Dolores and Mayado, Andrea and Jara-Acevedo, María and García-Montero, Andrés C and Orfao, Alberto and Álvarez-Twose, Iván},
  title = {Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals},
  journal = {Allergy},
  year = {2024},
  doi = {10.1111/all.15911}
}
Kostenlos starten →